Clinical Trial News and Research

RSS

BioLife Solutions first-quarter revenue up 36% to $513,000

BioLife Solutions, Inc., announced today that Chairman and Chief Executive Officer Mike Rice issued the following letter to shareholders providing a general corporate update.

20 May 2010

PurGenesis completes development of novel anti-aging cosmeceutical products

PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.

20 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

Cato Research to provide etrials EDC solution through Merge Healthcare's technology transfer program

Merge Healthcare, a leading Health IT solutions provider, announced today that it was selected by Cato Research Ltd. to provide the proprietary etrials EDC solution through Merge's technology transfer program. This new agreement expands Merge's partnership with CATO to provide additional technology for clinical trials management, as well as extending the relationship for an additional five years.

20 May 2010

Grifols reaches agreement with Pharmalink to acquire PPS drug development project

Today, Grifols SA announced that it has reached an agreement with the Swedish company Pharmalink AB to acquire various forms of intellectual property associated with the treatment of post-polio syndrome. The acquisition is expected to be finalized in the next few weeks and will include documentation, know-how, and Swedish regulatory approvals under the trade name Xepol.

20 May 2010

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

20 May 2010

Saint Louis University conducts research to find safe, effective vaccination for dengue

Sponsored by the National Institutes of Health, Saint Louis University's Center for Vaccine Development is conducting research of an investigational vaccine designed to prevent people from contracting dengue, a potentially lethal virus that has rapidly spread around the world.

20 May 2010

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis, during an oral presentation at the American Thoracic Society 2010 International Conference May 14 - 19, 2010 in New Orleans, LA.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.

20 May 2010

Medtronic commences treatment in RESCUE trial of Valiant Thoracic Stent Graft with Captivia Delivery System

Further demonstrating its commitment to proving the benefits of minimally-invasive procedures, Medtronic, Inc., today announced that the first patient has been treated with the company's Valiant® Thoracic Stent Graft with the Captivia Delivery System in Medtronic's RESCUE Clinical Study.

20 May 2010

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Cell Therapeutics, Inc. reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the 1st line treatment of high risk patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL, NHL).

19 May 2010

Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin

Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin 100mg compared with placebo, according to new research announced today. Flibanserin is an investigational, non-hormonal treatment being developed by Boehringer Ingelheim for pre-menopausal women with HSDD.

19 May 2010

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).

19 May 2010

Two common operations for SUI help women achieve similar levels of dryness: Study

Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.

19 May 2010

AP examines HIV microbicides, prep research

"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.

19 May 2010

Opinions: Gender-based violence and HIV; AIDS vaccine; Global NTDs; Responses to NYT HIV/AIDS articles

"Gender-based violence is a world-wide pandemic and directly affects the spread of HIV/AIDS. Fear of violence limits the ability of women and girls to choose their partners; to find out about a partner's HIV status or disclose their own; and to get medical or counseling services," according to a U.S. government editorial in VOA News.

19 May 2010

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

The probiotic yogurt-like drink DanActive reduced the rate of common sicknesses such as ear infections, sinusitis, the flu and diarrhea in daycare children, say researchers who studied the drink in the largest known probiotic clinical trial to be conducted in the United States. An additional finding, however, showed no reduction in the number school days missed.

19 May 2010

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Among more than 5000 poster abstracts, Aprea AB has been selected to present a poster at the annual American Society of Clinical Oncology (ASCO) Meeting in Chicago. The presentation will describe the scientific rational and design of the ongoing phase I/II clinical trial with Aprea's drug candidate APR-246.

19 May 2010

Clinical Trial News and Research

BioLife Solutions first-quarter revenue up 36% to $513,000

PurGenesis completes development of novel anti-aging cosmeceutical products

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Cato Research to provide etrials EDC solution through Merge Healthcare's technology transfer program

Grifols reaches agreement with Pharmalink to acquire PPS drug development project

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Saint Louis University conducts research to find safe, effective vaccination for dengue

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

Medtronic commences treatment in RESCUE trial of Valiant Thoracic Stent Graft with Captivia Delivery System

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Two common operations for SUI help women achieve similar levels of dryness: Study

AP examines HIV microbicides, prep research

Opinions: Gender-based violence and HIV; AIDS vaccine; Global NTDs; Responses to NYT HIV/AIDS articles

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News